Stoke Therapeutics, Inc.: management transactions · United States · SEC (Form 4)

About Stoke Therapeutics, Inc.

Stoke Therapeutics, Inc. (ticker: STOK) is a U.S.-listed biotechnology company trading on the NASDAQ in the United States, with core operations centered in Bedford/Cambridge, Massachusetts. Founded in 2014, the company was co-founded by Adrian Krainer, Ph.D. and Isabel Aznarez, Ph.D. around a proprietary scientific approach called TANGO, designed to increase protein expression by modulating pre-mRNA splicing. That platform gives Stoke a differentiated profile within the rare-disease biotech universe, where targeted RNA-based approaches are increasingly competing with gene therapy, ASOs, and other precision-medicine modalities. Stoke’s business model is built on developing disease-modifying medicines for severe genetic disorders by addressing the underlying biology rather than only managing symptoms. Its lead investigational program is zorevunersen (STK-001), being developed for Dravet syndrome, a severe and progressive genetic epilepsy. Management has consistently framed zorevunersen as the company’s first and most advanced clinical asset, and Stoke has also highlighted earlier-stage research efforts in dominant optic atrophy (ADOA) and SYNGAP1-related disorders. For investors, this means the company is still highly concentrated around one lead asset, but with a pipeline strategy aimed at creating optionality over time. From a competitive standpoint, Stoke operates in a niche where scientific credibility, durability of clinical effect, and regulatory execution matter more than near-term revenue scale. The company’s collaboration with Biogen on zorevunersen is strategically important: it provides external validation, broader development support, and a pathway toward eventual commercialization, while also sharing development risk. In the rare epilepsy space, where patient populations are small but unmet need is high, successful differentiation depends on meaningful clinical benefit and a tolerable safety profile. Geographically, Stoke is a U.S.-based company, but its late-stage development program is global in scope. The EMPEROR Phase 3 study has been conducted with recruitment in the U.S., the U.K., and Japan, underscoring the company’s intent to build an international regulatory package. Recent company updates in 2025 and 2026 emphasized continued progress in the Phase 3 program, long-term follow-up data from open-label extension studies, and increased focus on commercialization readiness. Those updates are important because they suggest Stoke is moving from a purely research-driven posture toward a more execution-oriented phase. Recent SEC Form 4 insider transaction filings related to STOK also indicate ongoing insider activity, including sales executed under 10b5-1 plans. Such transactions are common in public biotech companies and should be read cautiously; they are worth monitoring, but they do not necessarily imply a change in the company’s fundamental outlook. Overall, Stoke Therapeutics remains a high-risk, high-upside U.S. biotech story on NASDAQ, with a distinctive RNA-medicine platform, a focused lead program, and material clinical and regulatory catalysts ahead.